Giuseppe Sconocchia

Giuseppe Sconocchia is an Associate Professor at UniCamillus University and a Full Member of the CNR Institute of Translational Pharmacology. He holds board certification in Hematology and Internal Medicine. His roles include former Acting Directorships at CNR institutes in Naples and Rome, and research affiliations at institutions like the NIH in the US and University of Basel. His research focuses on tumor immunology, immunotherapy, and autoimmune diseases, with contributions to NK cell biology and CAR-T cell engineering. He has authored/co-authored over 103 peer-reviewed publications and holds patents for immunotherapy technologies.

Research Interests: Dr. Sconocchia’s work centers on T-cell engineering, NK cell function in cancer, and immune checkpoint modulation. Key areas include CD16/CD32 chimeric receptors for CAR-T therapy, HLA-matched NK cell therapies, and the role of inflammatory markers in autoimmune diseases like rheumatoid arthritis. His lab has identified novel immune cell subsets and mechanisms in colorectal and breast cancers.

Recent Articles Trends: His 2024-2025 work emphasizes CAR-T cell innovation (CD64/CD3ζ receptors), genetic risk factors in breast cancer, and MRD-directed AML therapy. Earlier studies explored NK cell infiltration in tumors and CD8+ lymphocyte roles in colorectal cancer prognosis.

Labs/Teams: Leads immunology projects at CNR and collaborates internationally. His patented CD32 CAR-T technology (patent TO2014A000631) targets antibody-independent cancer cell killing.